4.7 Article

Recessive axonal Charcot-Marie-Tooth disease due to compound heterozygous mitofusin 2 mutations

Journal

NEUROLOGY
Volume 77, Issue 2, Pages 168-173

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3182242d4d

Keywords

-

Funding

  1. Medical Research Council
  2. Muscular Dystrophy Campaign
  3. NIH
  4. Department of Health's National Institute for Health Research Biomedical Research Centres
  5. Telethon-UILDM [GUP04009]
  6. ApoPharma
  7. AIFA (Italian Drug Administration)
  8. Italian Ministry of Health
  9. Telethon-Italia
  10. MRC UK
  11. Wellcome Trust
  12. Kidney Research UK
  13. NIHR
  14. Cambridge Biomedical Research Centre
  15. PBC Foundation
  16. MRC [G0802760, G0601943, G1001253, G108/638] Funding Source: UKRI
  17. Medical Research Council [G108/638, G1001253, G0601943, G0802760] Funding Source: researchfish

Ask authors/readers for more resources

Objective: Mutations in mitofusin 2 (MFN2) are the most common cause of axonal Charcot-Marie-Tooth disease (CMT2). Over 50 mutations have been reported, mainly causing autosomal dominant disease, though families with homozygous or compound heterozygous mutations have been described. We present 3 families with early-onset CMT2 associated with compound heterozygous MFN2 mutations. Transcriptional analysis was performed to investigate the effects of the mutations. Methods: Patients were examined clinically and electrophysiologically; parents were also examined where available. Genetic investigations included MFN2 DNA sequencing and dosage analysis by multiplex ligation-dependent probe amplification. MFN2 mRNA transcripts from blood lymphocytes were analyzed in 2 families. Results: Compound heterozygosity for MFN2 mutations was associated with early-onset CMT2 of varying severity between pedigrees. Parents, where examined, were unaffected and were heterozygous for the expected mutations. Four novel mutations were detected (one missense, one nonsense, an intragenic deletion of exons 7 + 8, and a 3-base pair deletion), as well as 2 previously reported missense mutations. Transcriptional analysis demonstrated aberrant splicing of the exonic deletion and indicated nonsense-mediated decay of mutant alleles with premature truncating mutations. Conclusions: Our findings confirm that MFN2 mutations can cause early-onset CMT2 with apparent recessive inheritance. Novel genetic findings include an intragenic MFN2 deletion and nonsense-mediated decay. Carrier parents were asymptomatic, suggesting that MFN2 null alleles can be nonpathogenic unless coinherited with another mutation. Neurology(R) 2011;77:168-173

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available